Gazyva: Phase III data

The open-label, international Phase III GOYA trial in 1,418 previously untreated patients with CD20-positive DLBCL showed that 1,000 mg IV Gazyva every 3 weeks for 24 weeks plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) missed the primary endpoint of improving PFS vs. Rituxan rituximab plus CHOP chemotherapy. ...